Cascadian Therapeutics Inc (CASC) Received Average Rating of “Hold” from Brokerages

Cascadian Therapeutics Inc (CASC) Received Average Rating of “Hold” from Brokerages

Cascadian Therapeutics Inc (NASDAQ:CASC) has earned an average rating of “Hold” from the six analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $7.00.

CASC has been the subject of several analyst reports. Zacks Investment Research raised shares of Cascadian Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, February 7th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $10.00 target price (down from $15.00) on shares of Cascadian Therapeutics in a research note on Saturday, March 11th. BTIG Research began coverage on shares of Cascadian Therapeutics in a research note on Friday, April 21st. They issued a “buy” rating for the company. Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Tuesday, May 9th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $4.00 target price on shares of Cascadian Therapeutics in a research note on Wednesday, May 10th.

Shares of Cascadian Therapeutics (NASDAQ:CASC) traded up 2.01% during midday trading on Friday, hitting $4.06. 229,023 shares of the company’s stock traded hands. The firm’s market capitalization is $199.89 million. Cascadian Therapeutics has a 1-year low of $0.82 and a 1-year high of $6.72. The company has a 50 day moving average price of $4.17 and a 200 day moving average price of $4.13.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.09. Equities analysts anticipate that Cascadian Therapeutics will post $5.02 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. Perkins Capital Management Inc. increased its position in shares of Cascadian Therapeutics by 6.4% in the first quarter. Perkins Capital Management Inc. now owns 48,129 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 2,887 shares in the last quarter. BlueCrest Capital Management Ltd bought a new position in shares of Cascadian Therapeutics during the first quarter worth $122,000. Dimensional Fund Advisors LP bought a new position in shares of Cascadian Therapeutics during the first quarter worth $133,000. Citadel Advisors LLC bought a new position in shares of Cascadian Therapeutics during the first quarter worth $142,000. Finally, Bank of America Corp DE increased its position in shares of Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 35,975 shares in the last quarter.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CASC”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment